Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03527472 · ClinicalTrials.gov registry record · Phase 2

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

A Phase 2 study of Lupus Erythematosus, Systemic, sponsored by Vanderbilt University Medical Center.

Active
Registry status
Phase 2
Development phase
111
Enrollment target
3
Study locations

NCT03527472: Active Phase 2 study of Lupus Erythematosus, Systemic, sponsored by Vanderbilt University Medical Center.

NCT03527472 is a Phase 2 study of Lupus Erythematosus, Systemic that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 111 participants, below the 200-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (44% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03527472, a Phase 2 study of Lupus Erythematosus, Systemic, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
111 participants
Enrollment target
3
Study locations

Study Summary

A phenome-wide association study (PheWAS) identified an association between a variant in the human gene for the N2A subunit of the N-methyl-D-aspartate (NMDA) receptor, GRIN2A, and Systemic Lupus Erythematosus (SLE). A single nucleotide polymorphism (SNP) in this gene encodes for increased NMDA receptor activity. Based on the potential function of the associated SNP and published literature, alterations in SNP function signaling may underlie a cluster of symptoms. The objective of this study is to evaluate the safety, tolerability and efficacy of memantine, an NMDA receptor antagonist, in a precise patient subset with SLE. Participants will complete a full 14-week clinical trial, receiving either memantine or a placebo. Participants' blood will be drawn to test for various antibodies as well as organ function. Patients' urine will also be collected to assess organ function and pregnancy for females at a number of specific time points. The overall goal is to develop a safe and inexpensive therapeutic approach to reduce debilitating cognitive symptoms in a precisely selected SLE sub-population.

Primary Outcome

RBANS is a widely used psychiatric tool that objectively measures cognitive impairment. It is comprised of 12 subtests and takes approximately 30 minutes. For scoring, the RBANS index scores are converted to classifications including Very Superior (130 and above), Superior (120-129), High Average (110-119), Average (90-109), Low Average (80-89), Borderline (70-79), and Extremely Low (69 and below). A score of Extremely Low equates to severe cognitive impairment. The primary outcome measure will

Conditions Studied

Lupus Erythematosus, Systemic

Interventions

  • DRUG Placebo
  • DRUG Memantine

Study Locations (3)

Ohio

  • The Cleveland Clinic - Cleveland

Tennessee

  • Vanderbilt University Medical Center - Nashville

Texas

  • The University of Texas Health Science Center, Houston - Houston

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2018-08-23
Est. Completion 2026-02-28
Phase Phase 2
Vanderbilt University Medical Center

677 total trials

What the registry record for NCT03527472 still lists

NCT03527472 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 200-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (44% lower).

The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03527472 reports a single indexed study location in Ohio, Tennessee, Texas.

Frequently Asked Questions

What is clinical trial NCT03527472 about?

NCT03527472 is a clinical study titled "Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus". A phenome-wide association study (PheWAS) identified an association between a variant in the human gene for the N2A subunit of the N-methyl-D-aspartate (NMDA) receptor, GRIN2A, and Systemic Lupus Erythematosus (SLE). A single nucleotide polymorphism (SNP) in this gene encodes for increased NMDA rece...

What is the current status of trial NCT03527472?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2018-08-23. Estimated completion is 2026-02-28.

What conditions does trial NCT03527472 study?

This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.

What interventions are being tested in trial NCT03527472?

The interventions under investigation include: Placebo (DRUG), Memantine (DRUG).

Who is sponsoring clinical trial NCT03527472?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03527472 being conducted?

This trial has 3 study locations across Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Erythematosus, Systemic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03527472's enrollment target sits among peer trials

111 19th of 29 higher than 11 of 29 other Lupus Erythematosus, Systemic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lupus Erythematosus, Systemic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03875716 · 111 participants · NA

    Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

  • NCT04693468 · 111 participants · Phase 1

    Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

  • NCT05263050 · 111 participants · Phase 2

    Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

  • NCT05600842 · 111 participants

    De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03527472, the US trial registry maintained by the National Library of Medicine. NCT03527472 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.